The U.S. Food and Drug Administration has granted fast-track status to a Purdue University scientist’s optical imaging technology that may one day significantly improve outcomes for pancreatic cancer patients.
Philip Low, Purdue’s Ralph C. Corley Distinguished Professor of Chemistry and director of the Purdue Institute for Drug Discovery, developed the OTL 38 molecule that will move quickly to phase 3 clinical trials in human cancer patients. The molecule, given to patients intravenously, attaches to receptors on cancer cells and glows, identifying the cells that should be surgically removed. Read more . . .
Please note that this information is not intended to be a substitute for professional medical opinion, advice, or diagnosis. We encourage you to use this information to begin a dialogue with your physician about the treatment plan that is right for you.